NCT07353931ClinicalTrials.gov
Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
A Master Protocol for Phase 3 Randomized, Double-Blind, Placebo-Controlled Studies to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Osteoarthritis Knee Pain, and Obesity or Overweight (ENLIGHTEN-4)
باختصار
The YDAN master protocol will support two independent studies, J3R-MC-YOA1 and J3R-MC-YOA2. Each study will investigate how well and safely Eloralintide (LY3841136) works in adults with obesity or overweight who have osteoarthritis (OA) of the knee with pain. Participation in…
المرحلة 3مطلوب 900 مشارك152 موقعاً14 دولة
الفئات
مسجَّلة في سجل واحد
- ClinicalTrials.govNCT07353931فتح هذا السجل في ClinicalTrials.govتمت المزامنة قبل أسبوعين
يمكن أن تُسجَّل دراسة واحدة في عدة سجلات. نعرضها مرة واحدة ونربط بكل سجل نحتفظ به.
تُعرض معلومات التجربة كما نشرها السجل، بلغتها الأصلية.
هل أنت مهتم بهذه الدراسة؟
تسجيل الدخول أو أنشئ حسابًا لتسجيل اهتمامك ومتابعة هذه الدراسة.
How this study is set up
The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.
- Present: Registered before enrolment beganFirst posted 2026-01-21; recorded start 2026-02-09
- Present: Has a defined primary outcomeA primary outcome measure is listed in the record
- Present: The primary outcome states a time frameThe primary outcome measure records a time frame
- Present: Participants are randomly assignedAllocation is recorded as randomised
- Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
- Present: Uses blinding (masking)A masking level is recorded in the record
- Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
- Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
- Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
- Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
- Present: Sponsor has 347 other studies in this databaseCounted from the lead sponsor named in the record (Eli Lilly and Company)
- Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
- The record lists 2 conditions.
- Lead sponsor type recorded as: industry.
- Intervention regulatory context: investigational, within a phased regulatory pathway.
Trial stature
Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.
A strong methodological design for a phase 3 study, judged from its ClinicalTrials.gov record.
How this score is built
- Randomised allocation20/20
Participants are randomly allocated between arms
- Blinding13/20
Double-blind
- Control arm13/15
Placebo / sham control arm
- Primary-outcome specificity10/10
Named primary outcome with a defined time frame
- Endpoint type3/10
Surrogate or intermediate endpoint (conservative default)
- Multi-centre8/8
Multi-centre: 161 sites
- Data monitoring committee7/7
A data monitoring committee is in place
- Prospective registration5/5
Registered before the study start date
- Protocol / SAP posted0/5
No protocol or SAP posted to the registry
A large study, international in scope: 900 participants (target), run at 152 sites, across 14 countries.
How this score is built
- Enrolment29/40
900 participants (target)
- Site count24/25
161 sites
- Country count12/15
15 countries
- Planned duration7/10
Planned over about 27 months
- Sponsor scale9/10
Eli Lilly and Company has led 326 trials in our corpus
We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.
How this score is built
- Investigator standing0/100
No investigator recorded in the registry for this trial
These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.
ملخص
The YDAN master protocol will support two independent studies, J3R-MC-YOA1 and J3R-MC-YOA2. Each study will investigate how well and safely Eloralintide (LY3841136) works in adults with obesity or overweight who have osteoarthritis (OA) of the knee with pain. Participation in the study will last about 75 weeks, including screening.
الحالات
- Osteoarthritis
- Overweight or Obesity
الأهلية
| الجنس | الجميع |
|---|---|
| الأعمار | 18 Years – لا حد أقصى |
| المتطوعون الأصحّاء | لا |
الأهلية كما كُتبت في السجل
الأهلية في عبارات بسيطة
لم تُقسَّم معايير هذا السجل إلى عبارات منفصلة بعد. نص السجل أعلاه كامل وهو النسخة المُعتمَدة.
تصميم الدراسة
| نوع الدراسة | تدخّلية |
|---|---|
| المرحلة | المرحلة 3 |
| التخصيص | معشّاة |
| نموذج التدخّل | PARALLEL |
| الغرض الأساسي | TREATMENT |
| التعمية | DOUBLE (2) |
| التجنيد | مطلوب 900 مشارك |
الجهة الراعية والمتعاونون
- Eli Lilly and Company الجهة الراعية
الأذرع والتدخلات
- Eloralintide (YOA1)EXPERIMENTAL
Participants will receive eloralintide subcutaneously (SC)
- Placebo (YOA1)PLACEBO_COMPARATOR
Participants will receive placebo SC
- Eloralintide (YOA2)EXPERIMENTAL
Participants will receive eloralintide SC
- Placebo (YOA2)PLACEBO_COMPARATOR
Participants will receive placebo SC
التدخلات
- دواء Eloralintide
Administered SC
- دواء Placebo
Placebo administered SC
مقاييس النتائج
مقياس النتيجة الأولي
Percent Change from Baseline in Body Weight
Percent Change from Baseline in Body Weight
الإطار الزمني Baseline, Week 64
مقياس النتيجة الأولي
Change from Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score
Change from Baseline in the WOMAC Pain Subscale Score
الإطار الزمني Baseline, Week 64
مقياس النتيجة الثانوي
Change from Baseline in Systolic Blood Pressure (SBP)
Change from Baseline in SBP
الإطار الزمني Baseline, Week 64
مقياس النتيجة الثانوي
Percent Change from Baseline in Triglycerides
Percent Change in Baseline in Triglycerides
الإطار الزمني Baseline, Week 64
مقياس النتيجة الثانوي
Change from Baseline in Short Form-36 (SF-36 v2) Acute Form Physical Functioning Domain Score
Change from Baseline in SF-36 v2 Score
الإطار الزمني Baseline, Week 64
مقياس النتيجة الثانوي
Percent Change from Baseline in High Sensitivity, C-reactive Protein (hsCRP)
Percent Change from Baseline in hsCRP
الإطار الزمني Baseline, Week 64
مقياس النتيجة الثانوي
Change from Baseline in the WOMAC Physical Function Subscale Score
Change from Baseline in the WOMAC Physical Function Subscale Score
الإطار الزمني Baseline, Week 40, Week 64
مقياس النتيجة الثانوي
Change from Baseline WOMAC Pain Subscale Score
Change from Baseline WOMAC Pain Subscale Score
الإطار الزمني Baseline, Week 40
مقياس النتيجة الثانوي
Change from Baseline in Distance Walked During the 6-Minute Walk Test
Change from Baseline in Distance Walked During the 6-Minute Walk Test
الإطار الزمني Baseline, Week 64
مقياس النتيجة الثانوي
Change from Baseline in Body Mass Index (BMI)
Change from Baseline in BMI
الإطار الزمني Baseline, Week 64
مقياس النتيجة الثانوي
Change in Medication Use
Change in Medication Use
الإطار الزمني Baseline, Week 64
مقياس النتيجة الثانوي
Change from Baseline in SF-36v2 Acute Form Domain Scores With Exception of the Physical Functioning Domain Score
Change from Baseline in SF-36v2 Acute Form Domain Scores With Exception of the Physical Functioning Domain Score
الإطار الزمني Baseline, Week 64
مقياس النتيجة الثانوي
Change from Baseline in Health Status EQ-5D-5L Health State Utility
Change from Baseline in Health Status EQ-5D-5L Health State Utility
الإطار الزمني Baseline, Week 64
مقياس النتيجة الثانوي
Percent Change from Baseline in Fasting Insulin
Percent Change from Baseline in Fasting Insulin
الإطار الزمني Baseline, Week 64
مقياس النتيجة الثانوي
Percent Change from Baseline in Total Cholesterol
Percent Change from Baseline in Total Cholesterol
الإطار الزمني Baseline, Week 64
مقياس النتيجة الثانوي
Change from Baseline in Waist Circumference
Change from Baseline in Waist Circumference
الإطار الزمني Baseline, Week 64
مقياس النتيجة الثانوي
Percent Change from Baseline in Hemoglobin A1c (HbA1c)
Percent Change from Baseline in HbA1c
الإطار الزمني Baseline, Week 64
مقياس النتيجة الثانوي
Change from Baseline in WOMAC Stiffness Subscale Score
Change from Baseline in WOMAC Stiffness Subscale Score
الإطار الزمني Baseline, Week 64
مقياس النتيجة الثانوي
Change from Baseline in WOMAC Total Score
Change from Baseline in WOMAC Total Score
الإطار الزمني Baseline, Week 64
مقياس النتيجة الثانوي
Achievement of Improved Categorical Shift in Patient Global Impression of Severity (PGIS) - Target Knee Pain
Achievement of Improved Categorical Shift in PGIS - Target Knee Pain
الإطار الزمني Baseline, Week 64
مقياس النتيجة الثانوي
Achievement of Improved Categorical Shift in Patient Global Impression of Severity (PGIS) - Target Knee Function
Achievement of Improved Categorical Shift in PGIS - Target Knee Function
الإطار الزمني Baseline, Week 64
مقياس النتيجة الثانوي
Change from Baseline in Average Pain Intensity Numeric Rating Scale (API-NRS) Score
Change from Baseline in API-NRS Score
الإطار الزمني Baseline, Week 64
مقياس النتيجة الثانوي
Change from Baseline in Worst Pain Intensity Numeric Rating Scale (WPI-NRS) Score
Change from Baseline in WPI-NRS Score
الإطار الزمني Baseline, Week 64
مقياس النتيجة الثانوي
Pharmacokinetics (PK): Maximum Concentration at Steady State (Cmax, ss)
PK: Cmax, ss
الإطار الزمني Baseline through Week 64
مقياس النتيجة الثانوي
PK: Area Under the Concentration Versus Time Curve for One Dosing Interval at Steady State (AUC(0-T)ss)
PK: AUC(0-T)ss
الإطار الزمني Baseline through Week 64
مقياس النتيجة الثانوي
Number of Participants with Allowed Concomitant Pain Medication
Number of Participants with Allowed Concomitant Pain Medication
الإطار الزمني Baseline, Week 64
التواريخ
| تاريخ البدء | 9 فبراير 2026 (فعلي) |
|---|---|
| الإتمام الأولي | 1 مارس 2028 (تقديري) |
| الإتمام | 1 مايو 2028 (تقديري) |
| أول نشر | 21 يناير 2026 (فعلي) |
| آخر تحديث | 8 سبتمبر 2026 |
| النتائج منشورة | غير مذكور في سجل السجل |
| آخر تأكيد للحالة | سبتمبر 2026 |
فعلي يعني أن الحدث وقع. تقديري يعني أن الجهة الراعية تتوقعه. للكلمتين معنيان مختلفان.
المواقع
126 موقعاً قيد التجنيد
Argentina
| المنشأة | المدينة | الولاية أو المنطقة | الحالة |
|---|---|---|---|
| Centro Privado de Medicina Familiar / Mindout Research | Buenos Aires | لم يبدأ التجنيد بعد | |
| Centro Médico Arsema | Buenos Aires | لم يبدأ التجنيد بعد | |
| Stat Research S.A. | Buenos Aires | لم يبدأ التجنيد بعد | |
| Organizacion Medica de Investigacion | Buenos Aires | لم يبدأ التجنيد بعد | |
| CARDIAMET Investigaciones Médicas | Buenos Aires | لم يبدأ التجنيد بعد | |
| Centro de Investigaciones Clínicas Baigorria | Granadero Baigorria | لم يبدأ التجنيد بعد | |
| INECO Neurociencias Oroño | Rosario | لم يبدأ التجنيد بعد | |
| Instituto Especialidades de la Salud Rosario | Rosario | لم يبدأ التجنيد بعد | |
| Centro de Investigaciones Médicas Tucuman | SAN M. de Tucuman | لم يبدأ التجنيد بعد | |
| Medicina Reumatológica | San Fernando | لم يبدأ التجنيد بعد | |
| Instituto de Alta Complejidad San Isidro | San Isidro | لم يبدأ التجنيد بعد | |
| Centro Polivalente de Asistencia e Investigacion Clinica - CER San Juan | San Juan | لم يبدأ التجنيد بعد | |
| Centro de Investigaciones Reumatológicas | San Miguel de Tucumán | لم يبدأ التجنيد بعد | |
| Go Centro Medico San Nicolás | San Nicolás | لم يبدأ التجنيد بعد |
Belgium
| المنشأة | المدينة | الولاية أو المنطقة | الحالة |
|---|---|---|---|
| Antwerp University Hospital | Edegem | قيد التجنيد | |
| Reuma Clinic, Locatie Jaarbeurslaan | Genk | قيد التجنيد | |
| UZ Gent | Ghent | قيد التجنيد | |
| Kormont | Kluisbergen | قيد التجنيد | |
| UZ Leuven | Leuven | قيد التجنيد | |
| Meclinas | Mechelen | قيد التجنيد | |
| ZNA Jan Palfijn | Merksem | لم يبدأ التجنيد بعد | |
| Medisch Centrum Latem (Hip Clinic) - Algemeen Ziekenhuis Maria Middelares Location | Sint-Martens-Latem | لم يبدأ التجنيد بعد |
Brazil
| المنشأة | المدينة | الولاية أو المنطقة | الحالة |
|---|---|---|---|
| Centro de Pesquisa Sao Lucas | Campinas | مُعلَّق | |
| IBPClin - Instituto Brasil de Pesquisa Clínica | Rio de Janeiro | مُعلَّق | |
| CPHosp Medicina, Ensino e Pesquisa (CPQuali) | São Paulo | مُعلَّق | |
| INTEGRA - Pesquisa Clínica e Infusões | São Paulo | مُعلَّق | |
| CEPIC - Centro Paulista de Investigação Clínica | São Paulo | مُعلَّق | |
| Hospital das Clinicas FMUSP | São Paulo | مُعلَّق |
Canada
| المنشأة | المدينة | الولاية أو المنطقة | الحالة |
|---|---|---|---|
| Apex Trials | Guelph | قيد التجنيد | |
| G.R.M.O. (Groupe de recherche en maladies osseuses) Inc. | Québec | لم يبدأ التجنيد بعد | |
| Diex Recherche Inc. Division Quebec | Québec | قيد التجنيد | |
| Stouffville Medical Research Institute Inc. | Stouffville | قيد التجنيد | |
| Maple Leaf Research | Toronto | قيد التجنيد | |
| Dr. Anil K. Gupta Medicine Professional Corporation | Toronto | قيد التجنيد | |
| Diex Recherche Inc. Division Victoriaville | Victoriaville | قيد التجنيد |
China
| المنشأة | المدينة | الولاية أو المنطقة | الحالة |
|---|---|---|---|
| Beijing Ji Shui Tan Hospital | Beijing | قيد التجنيد | |
| The First Afflilated Hospital of Bengbu Medical College | Bengbu | قيد التجنيد | |
| Jilin Province People's Hospital | Changchun | قيد التجنيد | |
| The Second Hospital of Jilin University | Changchun | لم يبدأ التجنيد بعد | |
| Xiangya Hospital Central South University | Changsha | قيد التجنيد | |
| 2nd Affiliated Hospital Chongqing Medical Universi | Chongqing | قيد التجنيد | |
| The Second Affiliated hospital of Zhejiang University school of medicine | Hangzhou | قيد التجنيد | |
| The Second People's Hospital of Hefei | Hefei | قيد التجنيد | |
| Jinan Central Hospital | Jinan | قيد التجنيد | |
| The First Affiliated Hospital of Henan University of Science &Technology | Luoyang | قيد التجنيد | |
| Nanjing First Hospital | Nanjing | قيد التجنيد | |
| Zhongda Hospital Southeast University | Nanjing | قيد التجنيد | |
| The Second Affiliated Hospital of Nanjing Medical University | Nanjing | قيد التجنيد | |
| Jiangsu Province Hospital | Nanjing | قيد التجنيد | |
| The first affiliated hospital of Ningbo university | Ningbo | قيد التجنيد |
يُدرَج 102 موقع إضافي في سجل السجل.
مستندات الدراسة
لا تُرتبط أي مستندات في سجل السجل هذا.
التغيّرات عبر الزمن
- 6 أغسطس 2026
أُزيل موقع
9 sites removed (152 total)
161152